Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1997-01-16
2000-01-11
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
435 5, 435 71, 435 691, 435 693, 4352523, 4353251, 4353201, 4352351, 43525333, 530350, 530403, 536 2372, A61K 3912, C12Q 170, C12N 1534
Patent
active
060132620
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
THIS INVENTION relates to the L1 protein papilloma viruses. In particular, the invention relates to recombinant papilloma virus L1 protein and its use for detecting and treating papilloma virus infections.
BACKGROUND OF THE INVENTION
Papilloma viruses infect a range of hosts including man, cattle, sheep, dogs and cats. For a more complete listing, see "Papilloma Virus Infections in Animals" by J. P. Sundberg which is described in Papilloma Viruses and Human Diseases, edited by K. Syrjanen, L. Gissman and L. G. Koss, Springer Verlag, 1987.
Human papilloma viruses induce benign hyperproliferative lesions of the cutaneous and mucosal epithelia. Of the 70 different virus types which infect humans, more than 20 are associated with anogenital lesions (de Villiers, 1989, J. Virol. 63 4898-4903). Papilloma viruses have also been associated with various forms of cancers. Human papilloma virus types 16 and 18 have been associated with a number of cervical intra-epithelial neoplasias and carcinomas of the cervix (Lancaster et al., 1987, Cancer Metast. Rev. 6 6653-6664 and Pfister, 1987, Adv. Cancer Res. 48 113-147).
Papilloma viruses are small DNA viruses encoding up to eight early and two late genes. The late genes L1 and L2 code for structural proteins which assemble into a capsid within the cell (Galloway et al., 1989, Adv. Virus Res. 37 125-171). A single virus capsid is a T=7d icosahedron composed of 360 pentameric capsomers, each of which contains five molecules of the major capsid protein L1 (Baker et al., 1991, Biophys. J. 60 1445-1456 and Finch et al., 1965, J. Mol. Bio. 13 1-12). The minor capsid protein L2 is present at approximately one-tenth the abundance of L1 (Doorbar et al., 1987, J. Virol. 61 2793-2799).
Propagation of human papilloma viruses in vitro has not been achieved (Taichman et al., 1984, J. Invest. Dermatol. 83 25) and only small amounts of HPV proteins have been isolated from infected tissues (Androphy etal., 1987, Embo J. 6 1989; Banks et al., 1987, J. Gen. Virol. 68 1351; Firzlaff et al., 1988, Virology 164 467; Oltersdorf et al., 1987, J. Gen. Virol. 68 2933; Schneider-Gadicke et al., 1988, Cancer Res. 48 2969; Seedorf et al., Embo J. 6 139 and Smotkin et al., 1986, PNAS 83 4680). However, the gene coding for L1 protein has been cloned and expressed in a eukaryotic expression system using recombinant vaccinia virus (Browne etal., 1988, J. Gen. Virol. 69 1263-1273; Zhou et al., 1990, J. Gen. Virol. 71 2185-2190 and Zhou et al., 1991, Virology 185 251-257), in a baculovirus expression system (Park et al., 1993, J. Virol. Meth. 45 303-318) and in a bacterial expression system (Strike et al., 1989, J. Gen. Virol. 70 543-555).
As L1 protein is the major capsid protein, it has been used as the basis for the development of vaccines for protection against papilloma virus infection. Zhou et al. immunized mice with synthetic HPV16 virus-like particles (VLPs) using a vaccinia virus doubly recombinant for the L1 and L2 proteins of HPV16. The murine anti-VLP anti-sera recognised HPV16 capsids by ELISA and baculovirus recombinant HPV16L1 and L2 protein on immunoblot. The murine anti-VLP anti-sera, however, failed to recognise two peptides that were recognised by anti-HPV16L1 monoclonal antibodies raised against a recombinant L1 fusion protein (Zhou et al., 1992, Virology 189 592-599). These researchers concluded that the immunoreactive epitopes of HPV16 defined using virus-like particles differ significantly from those defined using recombinant HPV16L1 fusion proteins.
To overcome problems of presentation, vaccines were developed using virus-like particles. VLPs were formed intracellularly from recombinant L1 or L1 and L2 proteins encoded by recombinant vaccinia virus (Zhou et al., 1991, Virology 185 251-257; Zhou et al., 1991, Virology 181 203-210 and International Patent Specification WO93/02184). These vaccines using synthetic virus-like particles have a number of disadvantages. Firstly, the recombinant L1 or L1 and L2 genes are expressed from a vaccinia virus vector whic
REFERENCES:
patent: 5855891 (1999-01-01), Lowy et al.
Rose et al. 1993, J. of Virology, vol. 67 (4), pp. 1936-1944.
Pohlner et al, 1993, Gene, vol. 130 (1), pp. 121-126.
H. M. Browne et al., "Analysis of the L1 Gene Product of Human Papillomavirus Type 16 by Expression in a Vaccinia Virus Recombinant", J. Gen. Virol., vol. 69, (1988), pp. 1263-1273.
D. S. Park et al., "Human Papillomavirus Type 16 E6, E7 and L1 and Type 18 E7 Proteins by Recombinant Baculoviruses", Journal of Virological Methods, vol. 45, (1993), pp. 303-318.
D. G. Strike et al., "Expression in Escherichia Coli of Seven DNA Fragments Comprising the Complete L1 and L2 Open Reading Frames of Human Papillomavirus Type 6b and Localization of the `Common Antigen` Region", J. Gen. Virol., vol. 70, (1989), pp. 543-555.
J. Zhou et al., "Definition of Linear Antigenic Regions of the HPV16 L1 Capsid Protein Using Synthetic Virion-Like Particles", Virology, vol. 189, (1992), pp. 592-599.
J. Zhou et al., "The Induction of Cytotoxic T-Lymphocyte Precursor Cells by Recombinant Vaccinia Virus Expressing Human Papillomavirus Type 16 L1", Virology, vol. 181, (1991), pp. 203-210.
E. J. Androphy et al., "Identification of the HPV-16 E6 Protein from Transformed Mouse Cells and Human Cervical Carcinoma Cell Lines", The EMBO Journal, vol. 6, No. 4, (1987), pp. 989-992.
L. Banks et al., "Identification of Human Papillomavirus Type 18 E6 Polypeptide in Cells Derived from Human Cervical Carcinomas", J. Gen. Virol., vol. 68, (1987), pp. 1351-1359.
J. M. Firzlaff et al., "Detection of Human Papillomavirus Capsid Antigens in Various Squamous Epithelial Lesions Using Antibodies Directed Againse the L1 and L2 Open Reading Frames", Virology vol. 164, (1988), pp. 467-477.
T. Oltersdorf et al., "Identification of Human Papillmavirus Type 16 E7 Protein by Monoclonal Antibodies", J. Gen. Virol., vol. 68, (1987), pp. 2933-2938.
A. Schneider-Gaedicke et al., "Identification of the Human Papillomavirus Type 18 E6 and E6 Proteins in Nuclear Protein Fractions from Human Cervical Carcinoma Cells Grown in the Nude Mouse or in Vitro", Cancer Research, vol. 48, Jun. (1988), pp. 2969-2974.
K. Seedorf et al., "Identification of Early Proteins of the human Papilloma Viruses Type 16 (HPV 16) and Type 18 (HPV 18) in Cervical Carcinoma Cells", The EMBO Journal, vol. 6, No. 1, (1987), pp. 139-144.
D. Smotkin et al., "Transcription of Human Papillmavirus Type 16 Early Genes in a Cervical Cancer and a Cancer-Derived Cell Line and Identification of the E7 Protein", Proc. Natl. Acad. Sci. USA, vol. 83, Jul. (1986), pp. 4680-4684.
Stauffer, S. et al. "Expression of human papillomavirus type 18(HPV18) capsid proteins in E. coli and mammillian cells,".
Experimentia: 26.sup.th Annual Meeting of the Swiss Societies for Experimental Biology.
(USGEB/USSBE), vol. 50, p. A9, XP002101770 Abstract S04-05, Feb. 1994.
"pTrcHis A, B, & C," Invitrogen Corporation Catalogue, XP-0021000097, pp. 46, 47, 60, and 61 (1992).
S.A. Jenison et al., "Characterization of Human Antibody-Reactive Epitopes Encoded by Human Papillomavirus Types 16 and 18," J. Virol., vol. 65, No. 3, pp. 1208-1218 (Mar. 1991).
E. Schwartz et al., "DNA Sequence and genome organization of genital human papillomavirus type 6b," EMBO Journal, vol. 2, No. 12, pp. 2341-2348 (1983).
Frazer Ian
Zhou Jian
Mosher Mary E.
Salimi Ali R.
The University of Queensland
LandOfFree
Recombinant papilloma virus L1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant papilloma virus L1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant papilloma virus L1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459851